News Related to Moderate to Severe Acute Pain

Related coverage linked through entity extraction aliases.

Health Canada Accepts Vertex's Suzetrigine New Drug Submission for Acute Pain

Aug 30, 2026

Health Canada accepted Vertex's New Drug Submission for suzetrigine, a selective NaV1.8 pain signal inhibitor for acute pain. The FDA-approved drug could become Canada's first new class of acute pain medicine in over 20 years.

Pain Market Valued at $4.5B in 2025, Driven by Non-Opioid Innovation and Pipeline Expansion

Jul 21, 2026

The acute pain market reached $4.5B in 2025, with 98% of pain drugs generic. Voltage-gated sodium channel inhibitors like Journavx offer non-opioid relief, while 39% of the pipeline uses non-small-molecule modalities.